Inhibrx Inc INBX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 10:25 AM EDT
34.27quote price arrow down-0.02 (-0.07%)
Volume
24,131
52 week range
14.31 - 39.79
Loading...
  • Open34.30
  • Day High34.35
  • Day Low34.20
  • Prev Close34.30
  • 52 Week High39.79
  • 52 Week High Date02/27/24
  • 52 Week Low14.31
  • 52 Week Low Date10/31/23

Key Stats

  • Market Cap1.792B
  • Shares Out52.28M
  • 10 Day Average Volume0.29M
  • Dividend-
  • Dividend Yield-
  • Beta2.87
  • YTD % Change-9.76

KEY STATS

  • Open34.30
  • Day High34.35
  • Day Low34.20
  • Prev Close34.30
  • 52 Week High39.79
  • 52 Week High Date02/27/24
  • 52 Week Low14.31
  • 52 Week Low Date10/31/23
  • Market Cap1.792B
  • Shares Out52.28M
  • 10 Day Average Volume0.29M
  • Dividend-
  • Dividend Yield-
  • Beta2.87
  • YTD % Change-9.76

RATIOS/PROFITABILITY

  • EPS (TTM)-5.03
  • P/E (TTM)-6.82
  • Fwd P/E (NTM)-8.31
  • EBITDA (TTM)-218.029M
  • ROE (TTM)-475.31%
  • Revenue (TTM)1.80M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-13,318.17%
  • Debt To Equity (MRQ)475.76%

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Inhibrx Inc

 

Content From Our Affiliates

Profile

MORE
Inhibrx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company’s pipeline is focused on oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, and INBRX-109. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the...
Mark Lappe
Chairman of the Board of Director, President, Chief Executive Officer, Co-Founder
Kelly Deck CPA
Chief Financial Officer
Address
11025 N. Torrey Pines Road, Suite 200
La Jolla, CA
92037
United States

Top Peers

SYMBOLLASTCHG%CHG
FUSN
Fusion Pharmaceuticals Inc
21.43+0.01+0.07%
EWTX
Edgewise Therapeutics Inc
21.03+0.69+3.39%
SNDX
Syndax Pharmaceuticals Inc
22.73+0.23+1.02%
VERA
Vera Therapeutics Inc
44.58-0.96-2.11%
KURA
Kura Oncology Inc
20.75-0.26-1.24%